Top Insights
The Otsuka Pharmaceutical and Click Therapeutics mobile app Rejoyn received FDA clearance for use as an adjunct to medication in the treatment of major depressive disorder. But Otsuka must overcome hurdles facing digital therapeutics products, which have yet to gain traction among payers.
Recent Posts
Categories
Related Articles
What you need to know about Limb Amputation Surgery: Causes, Risks, and Recovery?
Have you ever wondered what happens when a limb Amputation is a...
Links
Employee opinions on their health insurance. Republican vs. Democratic physicians. States’ perspective...
There’s an Opportunity for More Providers to Partner with the 988 Lifeline, Execs Say
Two executives at behavioral health care companies discussed why it’s important for...
Media Call: What a Second Trump Administration May Mean for Health Care
Former President Trump’s return to the White House in 2025 could bring...
Leave a comment